Roivant Sciences Q2 EPS $(0.40) Vs. $(0.42) Last Year, Sales $37.10M Beat $29.39M Estimate
Portfolio Pulse from Benzinga Newsdesk
Roivant Sciences (NASDAQ:ROIV) reported a narrower Q2 loss of $(0.40) per share compared to $(0.42) last year, and sales of $37.10M, surpassing the $29.39M estimate, marking a 196.05% increase from $12.53M in the same period last year.
November 13, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roivant Sciences reported a smaller loss per share and a significant sales increase in Q2, beating analyst expectations.
The positive earnings report, with reduced losses and sales that significantly exceeded expectations, is likely to instill investor confidence and could lead to a short-term increase in ROIV's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100